Pelthos Therapeutics, Inc.

Contributing Author

Recent Articles by Pelthos Therapeutics, Inc.

Jan-13	Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance PTHS GlobeNewswire
Jan-05	Pelthos Therapeutics Acquires Xeglyze (abametapir) Topical Treatment for Head Lice PTHS -9.03% GlobeNewswire
Dec-23	Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn PTHS GlobeNewswire
Dec-04	Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI (berdazimer) Topical Gel, 10.3% PTHS GlobeNewswire
Dec-02	Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference PTHS GlobeNewswire
Nov-13	Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results PTHS -7.27% GlobeNewswire
Nov-07	Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing PTHS -8.07% GlobeNewswire
Nov-05	Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 PTHS +6.47% GlobeNewswire
Oct-09	Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum PTHS -7.89% GlobeNewswire
Sep-08	Pelthos Therapeutics to Participate in Upcoming September Investor Conferences PTHS +13.96% GlobeNewswire
Sep-02	Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference PTHS -5.03% GlobeNewswire
Aug-18	Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update PTHS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.